NASDAQ:AMRX opened at $3.33 on Tuesday. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of 166.50, a P/E/G ratio of 0.18 and a beta of 1.17. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.52 and a current ratio of 2.31. The company has a 50 day moving average of $4.03. Amneal Pharmaceuticals has a 12-month low of $3.08 and a 12-month high of $6.21.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) last released its earnings results on Wednesday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.10. Amneal Pharmaceuticals had a return on equity of 53.73% and a net margin of 0.08%. The business had revenue of $497.63 million for the quarter, compared to analyst estimates of $500.68 million. On average, analysts expect that Amneal Pharmaceuticals will post 0.75 earnings per share for the current fiscal year.
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.